Tuesday, July 17, 2018      
Choose Language  

Alvocade - Bortezomib

Drug Name : Alvocade - Bortezomib
Drug Category : AntineoPlastics
Pharmacological Category: Proteasome Inhibitor/ مهار کننده پروتئازوم
Brand Name : Alvocade
Drug Forms :
ALVOCADE® is available for intravenous injection or subcutaneous use based on dosage form. Each single use vial contains 1 or 3.5 mg of BORTEZOMIB as a sterile lyophilized powder


There is no known specific antidote for BORTEZOMIB overdosage. In humans, fatal outcomes following the administration of more than twice the recommended therapeutic dose have been reported, which were associated with the acute onset of symptomatic hypotension and thrombocytopenia. In the event of an overdosage, the patient's vital signs should be monitored and appropriate supportive care given.

FDA Approval

On June 23, 2008, the U.S. Food and Drug Administration approved bortezomib for injection in patients with Multiple Myeloma.